In the present study, we selected TP53 as a prognostic marker because gliomas with 1p/19q co-deletions and TP53 mutations were previously shown to be mutually exclusive [8]; accordingly, we hypothesized that IDH mutant gliomas with wild-type TP53 would predominantly harbor 1p/19q co-deletions. The gene discussed is IDH2; the disease is central nervous system cancer.